Romidepsin (FK228, Depsipeptide)

製品コードS3020 別名:FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide)化学構造

分子量(MW):540.7

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

サイズ 価格(税別)  
JPY 26062.00
JPY 79182.00
JPY 115702.00

カスタマーフィードバック(6)

  • Concentration over time for each dose cohort of romidepsin (B).

    Blood, 2018, 131(4):397-407. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    PBMCs from a patient were incubated with diverse agents (2 μM Compound E, 2 nM Bortezomib and 1nM Romidepsin) for 48 hours. Apoptosis detection was performed by Annexin V/PI staining and analyzed by flow cytometry. Annexin V+/PI− (lower right quadrant) areas stand for early apoptotic cells, and Annexin V+/PI+ (upper right quadrant) areas stand for late apoptotic or necrotic cells.

    Leukemia, 2015, 29(3):556-66. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • Effects of combination of bort/romidepsin on HDAC6 inhibition and activation of ER stress signaling. HA cells were treated with combination of 15 nM bortezomib and 5 nM romidepsin or either drug alone for 24 hr. Expression of CHOP/GADD153 (green signals) and cleaved PARP (red signals) was detected by immunofluorescent staining. DAPI (blue signals) stained the cell nuclei.

    Int J Cancer 2014 135(12):2950-61. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    An HIV-Gag-SLYNTVATL-specific CTL clone was labeled with Alexa-Fluor555 conjugated cholera toxin subunit B either cultured with 500 nM SAHA or 25 nM romidepsin for 20 hours, or maintained as an untreated control. These effector cells were combined with SLYNTVATL peptide pulsed target cells, matched on the restricting allele, in a collagen matrix medium containing sytox green viability dye. These mixtures were then plated in three separate wells of an 8-well cover slip and imaged by time-lapse brightfield and fluorescent microscopy. A. Shown are representative fields of view from the no treatment (upper panel), 500 nM SAHA (middle panel), and 25 nM romidepsin (lower panel) conditions advancing in time from left to right. Time stamps are given in hh[ratio]mm format. Clones described in the results are indicated with yellow arrows and killed target cells are indicated with white arrows in the upper right panel.

    PLoS Pathog 2014 10(8), e1004287. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • PLZF-RARa–nonexpressing and -expressing PLZFRARβ3 cells were treated with 5 nmol/L romidepsin for the indicated time points. Induction of the DNA DSB marker γH2AX was measured by Western blotting. β-Actin was used as a loading control.

    Mol Cancer Ther 2013 12(8), 1591-604. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    Impacts of chromopeptide A and FK228 on G2/M transition regulators. PC3 and LNCaP cells were treated with chromopeptide A or FK228 at indicated concentrations for 24 h, and cells lysates were immunoblotted with the indicated antibodies.

    Acta Pharmacol Sin, 2017, 38(4):551-560. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

製品安全説明書

HDAC阻害剤の選択性比較

生物活性

製品説明 Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.
特性 More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
ターゲット
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
体外試験

Unlike TSA, the active form redFK of Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin is 17-23 times weaker than redFK in inhibiting these HDACs with IC50 of 36 nM, 47 nM, 510 nM, and 14 μM, respectively. Romidepsin treatment in HeLa cells induces histone acetylation and p21 expression with EC50 of 3.0 nM, more strongly than redFK with EC50 of 11 nM due to the instability of redFK. [1] In addition to G2/M arrest, Romidepsin treatment causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. [2] Romidepsin is 100 times more potent than TSA and 1,000,000 times more potent than butyrate in inhibiting the proliferation of the A549 cells. [3] Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. [5] Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. [6] In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. [7] Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. [9]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 Mnr0R4VtdCCYaXHibYxqfHliQYPzZZk> NH;5bXozNjVvMUWgcm0> MVG3NkBp MnPubY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? MmTMNlU4QTB7MEe=
U2932  NYPuO4JjS2WubDDWbYFjcWyrdImgRZN{[Xl? Mm\WNk42NTF3IH7N NFLteJo4OiCq NIDHZmRqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NHnpXmUzPTd7MEmwOy=>
OCI-LY7 MVzD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MoXtNk42NTF3IH7N NGr6bJg4OiCq MlzybY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NV7pXIMzOjV5OUC5NFc>
Farage NFj5dlRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MWOyMlUuOTVibl2= M3jq[VczKGh? NGm4OHNqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NYLEcmd1OjV5OUC5NFc>
LY7/EBV MmXQR4VtdCCYaXHibYxqfHliQYPzZZk> MlLxNk42NTF3IH7N NW\V[m13PzJiaB?= NX7TSmFRcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= M37mZ|I2PzlyOUC3
U2932/EBV NGfNOHJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGH4WpozNjVvMUWgcm0> NWS4V2JxPzJiaB?= NFG5cZhqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi MknTNlU4QTB7MEe=
HCT116 Mmq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\yOU02ODByIH7N MUGyOEBp NGrHTHhFVVOR M3fONYlv\HWlZYOgZ4VtdCCmZXH0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> M3fQdFI2PDl{NUG1
ACH-2 M{\zUWZ2dmO2aX;uJGF{e2G7 NUP3T5lXOS17IH7N M{fwblI1KGh? Mnv6bY5lfWOnczDITXYuOSCHbo[g[ZhxemW|c3nvci=> NEjac|YzPTF2OUS2Oy=>
MCF-10A NXnqOHluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnFcIdnUUN3ME2wMlE4yrFyLkCxJI5O NF7rSHYzPDl3NEi1Oi=>
MCF-7 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVexPZVjUUN3ME2xMlExyrFyLkKwJI5O NHXVengzPDl3NEi1Oi=>
SK-BR-3 M{Tremdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPv[oRzUUN3ME2xMlAxyrFyLkO1JI5O NULtOm9vOjR7NUS4OVY>
MDA-MB-231 NX71dFBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LqO2lEPTB;MD62POKyOC5zNDDuUS=> NGK4ZYQzPDl3NEi1Oi=>
PC3 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHCU3lKSzVyPUGuOlXDuTBwM{Wgcm0> NIflb3UzPDl3NEi1Oi=>
HCT116 NH3iZYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\STWM2OD1zLkCwxtExNjByIH7N M3yyVVI1QTV2OEW2
HCT116-p21-/- M3vze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3lTWM2OD1zLkK2xtExNjN5IH7N NFfybXYzPDl3NEi1Oi=>
S1 MoLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHDUYZKSzVyPUeuOlfDuTBwMkmgcm0> MkjONlQ6PTR6NU[=
SW620 MnL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWToeYVMUUN3ME2wMlk{yrFyLkK5JI5O NFrBVFczPDl3NEi1Oi=>
LOX-IMVI M1O1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\pfHZKSzVyPUCuPFfDuTBwMEOgcm0> MV6yOFk2PDh3Nh?=
UACC-62 M3fVcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jKfGlEPTB;MD61OuKyOC5zNjDuUS=> NFztUogzPDl3NEi1Oi=>
MDA-MB-435 MnPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnpPYdKSzVyPUCuPVDDuTBwME[gcm0> MVyyOFk2PDh3Nh?=
SF-295 NXLQRoU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwOElCtVAvOTVibl2= NGe3dnMzPDl3NEi1Oi=>
A549 NXzIeJFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTFwMkdCtVAvOjRibl2= M2X4TVI1QTV2OEW2
H460 NE\6XldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LlVWlEPTB;Mj61POKyOC56MDDuUS=> NV\3XIZHOjR7NUS4OVY>
EKVX MlKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrlUotKSzVyPUGuN|PDuTBwM{Sgcm0> MXiyOFk2PDh3Nh?=
H146 Mmn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF:2dFlKSzVyPUCuNlLDuTBwMEegcm0> MWGyOFk2PDh3Nh?=
H526 NWHIVId1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jFOmlEPTB;MD6xOeKyOC5yMzDuUS=> M4X2SVI1QTV2OEW2
HuT-78 MoK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTFwN{RCtVAvPDRibl2= MVOyOFk2PDh3Nh?=
HA Ml63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWKwMlYzPS1zMH7N NEnmZZo1QCCq M3XDVYlv\HWlZYOgZUB{cWewaX\pZ4FvfGy7IIP0do9v\2W{IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vKGOxLYTy[YF1\WRid3n0bEBjd3K2ZYrvcYlj MkexNlQ4PzF3MUC=
MS-275 NFjkWYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{W0[lAvPjJ3LUGwcm0> Mk\zOFghcA>? NXK4R|l1cW6mdXPld{BiKHOrZ37p[olk[W62bImgd5Rzd26pZYKgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iY3:teJJm[XSnZDD3bZRpKGKxcoTlfo9ucWJ? MkTQNlQ4PzF3MUC=
CD4 T NYjXVJp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;JclQ5KGh? NYPXRYc3TUN3ME20MlXDuTFwMDDuUS=> M{PM[VI1PzJ{NEW0
CD4 T NUnESo1pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDYOFghcA>? NXvuS25wS0N3ME2xNFfDuTF{NjDuUS=> NFy2eXUzPDd{MkS1OC=>
CD4+ T MmPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;FR|UxRTNibl2= MnjXNlQ1QTVzMEW=
A549 M4TpOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV73RoZ6OTEkgKOxNFDDqG6P M2n1cVI1NzN4L{S4JIg> MkTnbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ M2P6TFI1PDh3N{m5
JJN3 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlK1NlQwPDhiaB?= NV24SXBSTUN3MEyx5qCKdk19IES45qCKcA>? NWnn[G5rOjRyM{CxOVA>
OPM-2 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV[0NI9COjRxNEigbC=> NWfzNmxZTUN3MIO9NgKBkW6POzC0PQKBkWh? NIDiRWwzPDB|MEG1NC=>
RPMI-8226 NIX5[VVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXH[nMzPC92ODDo NETH[I9GSzVyc{2xMljjiImwTUugOFjjiImq M{DaZlI1ODNyMUWw
U266 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXSyOE81QCCq M2PTPWVEPTC|PUGw5qCKdk19IES45qCKcA>? Ml75NlQxOzBzNUC=
CA46 NVPJ[oZJSXCxcITvd4l{KEG|c3H5 MorlOkBp NYL3WFk6cW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= NE\5No4zOzl4NkG2OC=>
DG75 MXzBdI9xfG:|aYOgRZN{[Xl? MlrwOkBp MYPpcoR2[2W|IH7vJIFxd3C2b4Ppdy=> MWOyN|k3PjF4NB?=
Ramos NWX0fpJXSXCxcITvd4l{KEG|c3H5 NITTS203KGh? NH7xNYNqdmS3Y3XzJIV5fGWwc3n2[UBieG:ydH;zbZM> NYXDV2xLOjN7Nk[xOlQ>
ST486 NEKwe2VCeG:ydH;zbZMhSXO|YYm= MVK2JIg> M{P2W4lv\HWlZYOg[Zh1\W6|aY\lJIFxd3C2b4Ppdy=> NUWw[VMzOjN7Nk[xOlQ>
HuT78 NX3ZUI1PSXCxcITvd4l{KEG|c3H5 MlHXNU8yOC9zMECgcm0> MVy0PEBp Mn7tbY5lfWOnczDhdI9xfG:|aYOgZZQhOSCwTR?= NELNPIUzOzV|MkezNi=>
DpVp35 NXHPSWJoSXCxcITvd4l{KEG|c3H5 NFfJfZYyNzFyL{GwNEBvVQ>? NGrjTYY1QCCq NH3hWVFqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= MmWyNlM2OzJ5M{K=
DpVp50 NIK2eoxCeG:ydH;zbZMhSXO|YYm= NVTOXoJZOS9zMD:xNFAhdk1? NV3OWmFvPDhiaB?= M4r3O4lv\HWlZYOgZox2dnRiYYDvdJRwe2m| MkPPNlM2OzJ5M{K=
DpP75  NWjZNpV{SXCxcITvd4l{KEG|c3H5 NFPZ[VIyNzFyL{GwNEBvVQ>? MXu0PEBp NXnzOJZKcW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= NXnOOHEyOjN3M{K3N|I>
SKOV-3 MnnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4G3ZlHjiJN{MH7N NF\n[2Q4OiCq NHXsRZBFVVOR M4W5[pJm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv MoLINlMxOTB|NEi=
Brca1 WT M1LuWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVSx5qCUOjCwTR?= M3T0RlczKGh? NWTKS5NWTE2VTx?= NVyyXZdDemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? Mo\uNlMxOTB|NEi=
Brca1 Null MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljlNgKBmzJybl2= NGX3SoU4OiCq M3ezZ2ROW09? MmmwdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> MnPTNlMxOTB|NEi=
OVCAR-8  MnvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnWxNgKBmzJybl2= NVT4SpdCPzJiaB?= NH3PfZNFVVOR Ml;SdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> NWXpe2pIOjNyMUCzOFg>
NCI/ADR-RES MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rMNlHjiJN{MH7N M2Dvb|czKGh? MnjsSG1UVw>? MmPvdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> Ml;rNlMxOTB|NEi=
HCT116 Mnq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVX1RoN{PSCwTT21NEDPxE1? MoXUNlQhcA>? MX3EUXNQ M37UbolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz MlK3NlI6OjR7NUi=
RKO MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HjelUhdk1vNUCg{txO M3;RNlI1KGh? MV;EUXNQ NIe3bJVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? MXWyNlkzPDl3OB?=
CO115 NFvnT3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXjOUBvVS13MDFOwG0> NFL5TG4zPCCq MonDSG1UVw>? M4rsPIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz MnHDNlI6OjR7NUi=
HFS NHG5dG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;aTpJ6PSCwTR?= NHLGcYMzPC92OD:3NkBp MVXpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nLXTldIVv\GWwdHz5 M3\COFIzOTB4Mkiy
LNCaP NXHxOWxrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELxdVE2KG6P NIjQNFUzPC92OD:3NkBp M{HmNIlvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWt[IVx\W6mZX70cJk> MkC3NlIyODZ{OEK=
A549 NYnWPIpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfLUnFXPSCwTR?= M4XDTFI1NzR6L{eyJIg> NHLuN5FqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lMYRmeGWwZHXueIx6 MlLONlIyODZ{OEK=
697  MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4S4SWlEPTEkgJm95qCKOi53wrDuUS=> NGTEXpMzOTV|OEKxOi=>
697-R MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHpTWM2OOLCiU5ihKk5NjcEoH7NxsA> M2PHOlIyPTN6MkG2
HUT78 NYjHXI51T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HSV2lEPTB;MTDuUS=> NXXDXlhsOjFzOUi1OFU>
THJ-16T Mor5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWKzPGF6OSCwTR?= NFLVT3AzPCCq NFLGNoRqdmirYnn0d{Bk\WyuIHfyc5d1cA>? M2HXUlIxQDFyNU[4
HCT116 NUWwTIlPTnWwY4Tpc44hSXO|YYm= NHjaTWgzOCCwTR?= NF7QeJQ5KGh? M1zVUo1w\HWuYYTld{B1emGwc3PybZB1KGyndnXsd{Bnd3JiaIXu[JJm\HNib3[g[4Vv\XNiaX6g[Yl1cGW{IHTpdoVkfGmxbh?= M3HQblIxPzN7NEW0
B104  MnfKSpVv[3Srb36gRZN{[Xl? NXXY[JhLOiCwTR?= NUP5cplIOjRxNEivO|IhcA>? M{j6eYlv[3KnYYPld{B1cGVic4Xy[oFk\SCneIDy[ZN{cW:wIH;mJGNFOjEEoB?= NWPDXVFROjB4OE[1NFU>
HL-60  NVrCSYRFS3m2b4TvfIlkcXS7IFHzd4F6 MVyxMVUxOCCwTR?= NVzDOYVXOjRiaB?= M2PFNolv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? NU\YWGdtOjB4MkSxOlM>
HP100 NIDO[WFEgXSxdH;4bYNqfHliQYPzZZk> M3jZXFEuPTByIH7N NYX6TWtjOjRiaB?= M1\ZOolv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? NYroRW5UOjB4MkSxOlM>
HL-60  NV:xeG9rTnWwY4Tpc44hSXO|YYm= MYexNEBvVQ>? NHrqb2g1NzZxMU[gbC=> M33VOolv\HWlZYOgeIhmKGenbnXyZZRqd25ib3[gbJllem:pZX6gdIVzd3irZHWg[pJwdSB2aB?= M{K4TVIxPjJ2MU[z
HP100 NF;3eZlHfW6ldHnvckBCe3OjeR?= M1W5N|ExKG6P MnToOE83NzF4IHi= NI\ON|VqdmS3Y3XzJJRp\SCpZX7ldoF1cW:wIH;mJIh6\HKxZ3XuJJBmem:6aXTlJIZzd21iNHi= NFLnOZEzODZ{NEG2Ny=>
HL-60  NVvWeWJuTnWwY4Tpc44hSXO|YYm= Mn;6NVAuPTByIH7N NIrjfVE1KGh? M1LLWoRm[3KnYYPld{B1cGViaHnzeI9v\SCmZXHj[ZR6dGG|ZTCoTGRCSyliYXP0bZZqfHoEoB?= MU[yNFYzPDF4Mx?=
HP100 NWPrUFd2TnWwY4Tpc44hSXO|YYm= M1HhTlExNTVyMDDuUS=> NEiyS4M1KGh? Mn\G[IVkemWjc3XzJJRp\SCqaYP0c45mKGSnYXPleJlt[XOnIDjISGFEMSCjY4Tpeol1gcLi NWGz[5dDOjB4MkSxOlM>
11z M1jLRWtqdmG|ZTDBd5NigQ>? MkDUN{0yODBibl2= NILmdYxz\WS3Y3XzJGhFSUNiZX76fY1ifGmlIHHjeIl3cXS7IDjJR|UxyqB;IE[uOUDDuSByLk[gco1wdC:OKR?= NE\tV5MzODZyNUG0OC=>
SKOV-3 MlOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYi0M|gwOTZibl2= NVrscpF2PDhiaB?= Mlr3bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> NIr4UpkzODRyNEW2OC=>
OVCAR-3 NX65XZdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfUXnBLPC96L{G2JI5O M2PzTVQ5KGh? M1nEVIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz Mmf4NlA1ODR3NkS=
HBL-2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1q4SFIuOTBibl2= MUOyOEBp MWPJR|UxRTRwMzDuUS=> NInpfYczODB4OEC4NC=>
Jeko-1 M1vIVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYWyMVUxKG6P NYHnTZNEOjRiaB?= M{S4dGlEPTB;MUGgcm0> M1fRblIxODZ6MEiw
Granta-519 NHO5OVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moj1OU01OCCwTR?= NVfteGpVOjRiaB?= NWW0d3hpUUN3ME21PE42KG6P NHntXZgzODB4OEC4NC=>
L1236 NH7hVJREgXSxdH;4bYNqfHliQYPzZZk> MlrGNUBvVS1zMECg{txO MmHYOFghcA>? MlfnSWM2OD1yLkC3JO69VQ>? M{DTU|E6OjN|NEew
L428 NVLyRlJ7S3m2b4TvfIlkcXS7IFHzd4F6 MojuNUBvVS1zMECg{txO MnLuOFghcA>? MV3FR|UxRTBwNEOg{txO NF62OFAyQTJ|M{S3NC=>
KM-H2 NHL6V49EgXSxdH;4bYNqfHliQYPzZZk> M1rQOVEhdk1vMUCwJO69VQ>? MVq0PEBp NXTE[pNNTUN3ME2wMlU5KM7:TR?= MoCwNVkzOzN2N{C=
L540Cy MVzDfZRwfG:6aXPpeJkhSXO|YYm= NVjBXIRnOSCwTT2xNFAh|ryP Mn7zOFghcA>? M2HGUWVEPTB;MD6xOkDPxE1? MUCxPVI{OzR5MB?=
G401 M3XBRmZ2dmO2aX;uJGF{e2G7 M1\TVlExKG6P MojoNlQwPDhxN{KgbC=> M3XYemROW09? M1vjPIlv[3KnYYPld{BETEuQMVOg[ZhxemW|c3nvci=> MW[xPVIzOTV6Nh?=
STM91-01 M2Tqb2Z2dmO2aX;uJGF{e2G7 NH23TI8yOCCwTR?= NW\0fYFKOjRxNEivO|IhcA>? Ml;CSG1UVw>? MnK3bY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u MlO2NVkzOjF3OE[=
SJSC  NV;VTplTTnWwY4Tpc44hSXO|YYm= NH\NVoQyOCCwTR?= MlLMNlQwPDhxN{KgbC=> NVTOOY51TE2VTx?= MUHpcoNz\WG|ZYOgR2RMVjGFIHX4dJJme3Orb36= NGPnOHkyQTJ{MUW4Oi=>
BT16  NYXRPYRKTnWwY4Tpc44hSXO|YYm= M1TjWlExKG6P MXiyOE81QC95MjDo M{niOWROW09? NH;NXZpqdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> NX7OTlQ4OTl{MkG1PFY>
NCI-H1299 M2XoRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPGTWM2OD12LkdCtVAvOiCwZz;tcC=> MV[xPVE4QTh7MB?=
NCI-2882 M1[3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlywTWM2OD1zLkdCtVAvODRibnevcYw> Mn\QNVkyPzl6OUC=
HCC95 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTJwNdMxNE4xPSCwZz;tcC=> MUCxPVE4QTh7MB?=
NCI-H23 NHvDe2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTvZnZvUUN3ME2yMlnDuTBwMjDu[{9udA>? NYr2NpdCOTlzN{m4PVA>
NCI-H157 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjJWGpVUUN3ME2xMlbDuTBwMEKgcocwdWx? MYqxPVE4QTh7MB?=
NCI-H460 MlL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LQTWlEPTB;Mj6xxtExNjB5IH7nM41t NHrBXmMyQTF5OUi5NC=>
NCI-H1975 MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHNTWM2OD1zLkRCtVAvODRibnevcYw> NF;WbmkyQTF5OUi5NC=>
NCI-H820 M3HZOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1S4NWlEPTB;Mj60xtExNjFibnevcYw> NUHmPYdNOTlzN{m4PVA>
NCI-H1650 M4PSUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUCyfpU4UUN3ME20MlnDuTBwMzDu[{9udA>? MkDzNVkyPzl6OUC=
DTC1 NX\XR45PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvjTWM2OD1yLkWxJI5O NWDvfW9FOTh3Nk[yOFY>
KAO NVPnU3VyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXn5elZsUUN3ME2wMlkyKG6P NXXaTo5SOTh3Nk[yOFY>
SU-CCS-1 NVuyVZZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTOTWM2OD1yLki5JI5O MWqxPFU3PjJ2Nh?=
SYO-1 M4\UbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\TN2lEPTB;MD62O{BvVQ>? MV[xPFU3PjJ2Nh?=
FUJI MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljKTWM2OD1zLkOxJI5O NXLBNIZiOTh3Nk[yOFY>
SKNMC NVj3UohiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PsSWlEPTB;MT6xO{BvVQ>? MnrzNVg2PjZ{NE[=
402-91 NX\6VXhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzRTWM2OD1zLkK2JI5O MYqxPFU3PjJ2Nh?=
1765-92 MmGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfETWM2OD1zLke3JI5O MW[xPFU3PjJ2Nh?=
JN-DSRCT-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTFwMkWgcm0> NGrhVZEyQDV4NkK0Oi=>
NMS-2PC M2\TT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnRPVJSUUN3ME2wMlgyKG6P MkXBNVg2PjZ{NE[=
HL60 NY\rOZJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTFwOE[gcm0> M1rhclE5PTZ4MkS2
A549 NWH2W486T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TLdmlEPTB;Mz6yOEBvVQ>? M2\vUFE5PTZ4MkS2
SW480 NF3WWFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkK4TWM2OD1{Lk[5JI5O M4PNWlE5PTZ4MkS2
MCF7 MmDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTNwNUWgcm0> NXTieXRlOTh3Nk[yOFY>
PC-3 MmflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfqTWM2OD1{LkWxJI5O MkHHNVg2PjZ{NE[=
MMRU Mmj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojDTWM2OD1{LkW3JI5O MoLmNVg2PjZ{NE[=
Hs68 NITHRWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jvbWlEPTB;PkGwJI5O NECxdlgyQDV4NkK0Oi=>
hMSC-001F NUTOdXBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHvSmRKSzVyPU6xNEBvVQ>? MlTaNVg2PjZ{NE[=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Romidepsin treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. [4]Administration of Romidepsin at 0.1-1 mg/kg twice a week significantly prolongs the survival of mice bearing U-937 lymphoma, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). [5]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
細胞試験:

[3]

+ 展開
  • 細胞株: HL60, Jurkat, A549, and MCF-7
  • 濃度: Dissolved in DMSO, final concentrations ~10 μM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of Romidepsin for 72 hours in 96-well plates. 20 μL of 5 mg/mL MTT solution in PBS is added to each well for 4 hours. After removal of the medium, 170 μL of DMSO is added to each well to dissolve the formazan crystals. The absorbance at 540 nm is determined. In addition, cells are incubated with trypan blue, and the numbers of blue (dead) cells and transparent (live) cells are counted in a hemocytometer. For cell cycle analysis, cells are incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide, 1 mM EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension is then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan.


    (参考用のみ)
動物試験:

[5]

+ 展開
  • 動物モデル: Male scid mice inoculated i.p. with U-937 cells
  • 製剤: Dissolved in DMSO, and diluted in saline
  • 投薬量: ~1 mg/kg once or twice a week
  • 投与方法: Treated i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 540.7
化学式

C24H36N4O6S2

CAS No. 128517-07-7
保管
in solvent
別名 FR 901228, NSC 630176

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03703375 Not yet recruiting Lymphoma T-Cell Celgene October 15 2018 Phase 3
NCT03547700 Recruiting Lymphoma T-Cell Peripheral Ryan Wilcox|University of Michigan Cancer Center|Takeda|Big Ten Cancer Research Consortium September 26 2018 Phase 1|Phase 2
NCT03355768 Not yet recruiting Lymphoma T-Cell Peripheral Jennifer Amengual|Columbia University September 2018 Phase 3
NCT03593018 Not yet recruiting Relapsed Angioimmunoblastic T-Cell Lymphoma|Refractory Angioimmunoblastic T-cell Lymphoma The Lymphoma Academic Research Organisation|Celgene September 2018 Phase 3
NCT03161223 Recruiting Lymphoma T-Cell Columbia University|University of Bologna|Samsung Medical Center|Celgene June 1 2018 Phase 1|Phase 2
NCT03432741 Recruiting Breast Adenocarcinoma|Recurrent Breast Carcinoma|Recurrent Hodgkin Lymphoma|Recurrent Mycosis Fungoides|Recurrent Non-Hodgkin Lymphoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|Refractory Mycosis Fungoides|Refractory Nodal Marginal Zone Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage IV Breast Cancer AJCC v6 and v7 Mayo Clinic|National Cancer Institute (NCI) March 27 2018 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

HDACシグナル伝達経路

HDAC Inhibitors with Unique Features

相関HDAC製品

Tags: Romidepsin (FK228, Depsipeptide)を買う | Romidepsin (FK228, Depsipeptide) ic50 | Romidepsin (FK228, Depsipeptide)供給者 | Romidepsin (FK228, Depsipeptide)を購入する | Romidepsin (FK228, Depsipeptide)費用 | Romidepsin (FK228, Depsipeptide)生産者 | オーダーRomidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)化学構造 | Romidepsin (FK228, Depsipeptide)分子量 | Romidepsin (FK228, Depsipeptide)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID